Article
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.
Signal transduction and targeted therapy - 2 Dec 2025
Shi Yuankai, Lv Dongqing, Feng Weineng, Liu Shuoyan, Xing Puyuan, Yu Yan, Yin Jun, Ren Xiubao, Zhang Junqiang, Han Gaohua, Zhang Yongchang, Cang Shundong, Chen Jun, Chen Enguo, Meng Lingxin, Zhang Yong
Abstract excerpt
Osimertinib, the first approved third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), exhibits notable efficacy in EGFR-mutant non-small cell lung cancer (NSCLC). This is a prospective, multicenter, comprehensive genomic profile signature (GPS) study in paired tissue and plasma samples from 149 patients with advanced NSCLC harboring EGFR exon 19 deletion (Ex19del) or L858R...
Topics
Join the communities discussing this publication.